| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.06 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.069 | 0.06 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.06 |